Neurocrine Biosciences
NBIX
NBIX
207 hedge funds and large institutions have $3.29B invested in Neurocrine Biosciences in 2015 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 81 increasing their positions, 78 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
207
Holders Change
+9
Holders Change %
+4.55%
% of All Funds
5.79%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
33
Increased
81
Reduced
78
Closed
23
Calls
$65M
Puts
$28.8M
Net Calls
+$36.2M
Net Calls Change
-$6.56M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$72.4M |
| 2 |
CCI
Columbus Circle Investors
|
+$18.4M |
| 3 |
TCP
Tourbillon Capital Partners
New York
|
+$18M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.9M |
| 5 |
CCM
Cadian Capital Management
New York
|
+$10.3M |
Top Sellers
| 1 |
PC
PointState Capital
New York
|
-$67.5M |
| 2 |
O
OrbiMed
New York
|
-$50.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$40.7M |
| 4 |
Axa
Paris,
France
|
-$13.8M |
| 5 |
PA
Perceptive Advisors
New York
|
-$13.6M |
